Oct 03, 2019 / 06:25PM GMT
Craig William Bijou - Cantor Fitzgerald & Co., Research Division - Research Analyst
Good afternoon. My name is Craig Bijou. I'm the medical device analyst here at Cantor Fitzgerald. Happy to have Zimmer Biomet here. And from Zimmer, Cole Lannum, senior Vice President of Investor Relations and IRO. So thank you, Cole.
Coleman N. Lannum - Zimmer Biomet Holdings, Inc. - SVP of IR
Absolutely, Craig. Good to be here.
Questions and Answers:
Craig William Bijou - Cantor Fitzgerald & Co., Research Division - Research AnalystSo you want to start with the turnaround of the business. Obviously, it's much talked about. You guys were 6 months ahead of schedule coming out of Q2. So maybe just kind of level set or provide a little bit of background of where you guys were, how you've -- how you are now, 6 months ahead of schedule, the steps you've taken. And then, what's next? Or what's left in the "turnaround?" What steps still need to be taken?
Coleman N. Lannum - Zimmer Biomet Holdings,
Trustpilot
